Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 11,177 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohort study Clear all

Conditions: Obesity
Interventions: PF-07081532, Semaglutide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Type 1 Diabetes
Interventions: Insulet Artificial Pancreas (AP) System; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 6 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Palo Alto, California • Santa Barbara, California • Walnut Creek, California + 1 more

Conditions: Adenocarcinoma of the Prostate
Interventions: Lycopene and Docetaxel; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage II Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions: adjuvant therapy, paclitaxel, carboplatin, bevacizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 17
States / cities: Orange, California • Chicago, Illinois • Iowa City, Iowa + 9 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 40 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 4 more

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: RSVpreF, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 920 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Durham, North Carolina • Cincinnati, Ohio • South Euclid, Ohio + 1 more

Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome
Interventions: aldesleukin, recombinant interleukin-12, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Vitiligo
Interventions: ruxolitinib, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 44
States / cities: Hoover, Alabama • Gilbert, Arizona • Fountain Valley, California + 36 more

Conditions: Non-Small-Cell Lung Cancer
Interventions: XL999; Drug
Lead sponsor: Symphony Evolution, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Detroit, Michigan + 2 more

Conditions: Cancer
Interventions: Harbinger Health Test; Diagnostic Test
Lead sponsor: Harbinger Health; Industry
Eligibility: 20 Years to 79 Years
Enrollment: 8,038 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 128
States / cities: Daphne, Alabama • Anchorage, Alaska • Prescott Valley, Arizona + 93 more

Conditions: Non Small Cell Lung Cancer
Interventions: AC0010MA; Drug
Lead sponsor: ACEA Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Duarte, California • Palo Alto, California • Atlanta, Georgia + 1 more

Conditions: Skin Wound, Burns, Trauma-related Wound
Interventions: StrataGraft; Biological
Lead sponsor: Stratatech, a Mallinckrodt Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Tumor, Colorectal Cancer
Interventions: NKTR-102 100 mg/m2, NKTR-102 125 mg/m2, Cetuximab; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Scottsdale, Arizona • Louisville, Kentucky • Dallas, Texas + 1 more

Conditions: Soft Tissue Sarcoma
Interventions: pegylated arginine deiminase, Gemcitabine, Docetaxel, Tumor biopsy, Research blood draw; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 10 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Palo Alto, California • Santa Monica, California • St Louis, Missouri + 1 more

Conditions: Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A
Interventions: No Investigational Product, Adjuvant Immunomodulatory (IM) Therapy; Other · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: Not listed
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy
Interventions: Sampling Rate; Other
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Glendale, California

Conditions: Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma, Follicular Lymphoma Grade 3B
Interventions: Mosunetuzumab, DHAX, ICE; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions: Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 42
States / cities: Hot Springs, Arkansas • Springdale, Arkansas • Beverly Hills, California + 36 more

Conditions: X-Linked Retinitis Pigmentosa
Interventions: AAV5-hRKp.RPGR; Biological
Lead sponsor: MeiraGTx Ocular UK Ltd; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Immunoglobulin A Nephropathy (IgAN)
Interventions: Felzartamab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 29
States / cities: Little Rock, Arkansas • Apple Valley, California • Carlsbad, California + 25 more

Conditions: Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Wilms Tumor, Desmoplastic Small Round Cell Tumor
Interventions: Enoblituzumab; Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 1 Year to 35 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 6
States / cities: Palo Alto, California • Bethesda, Maryland • Philadelphia, Pennsylvania + 3 more

Conditions: Gulf War Era Cohort
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 1,275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Advanced Cancer, Metastatic Solid Tumor
Interventions: BC3195; Drug
Lead sponsor: Biocity Biopharmaceutics Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Rheumatoid Arthritis (RA)
Interventions: ASP5094, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Anniston, Alabama • DeBary, Florida • Jacksonville, Florida + 4 more

Search by objective public record fields.

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

Insulet Artificial Pancreas Early Feasibility Study

Docetaxel and Lycopene in Metastatic Prostate Cancer

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Non-traditional Cardiovascular Risk Factors and Atherosclerosis in Type 2 Diabetes

Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

Development and Validation of Harbinger Health Test for Early Cancer Detection

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA

Exploratory Biomarker Study of Cerebrospinal Fluid in Healthy Volunteers

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Gulf War Era Cohort and Biorepository

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate